Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.68 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211004 | 1.00 | AHCY (0.68) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL13211005 | 0.95 | AHCY (0.71) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL3027682 | 0.95 | AHCY (0.71) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL13210999 | 0.82 | ENTPD1 (0.64) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL14178249 | 0.82 | ADORA3 (0.82) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| Neca SCHEMBL19928418 | 0.80 | TSHR (1.00) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| Neca SCHEMBL19928417 | 0.80 | TSHR (1.00) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| Neca SCHEMBL16585523 | 0.80 | TSHR (1.00) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| Neca SCHEMBL12119012 | 0.80 | TSHR (1.00) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| Neca SCHEMBL18089301 | 0.80 | TSHR (1.00) | AHCYADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | AHCY 598/4885ADORA3 28/4885ADORA2A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.